Journal article

Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C

Maryam Alavi, Tim Spelman, Gail V Matthews, Paul S Haber, Carolyn Day, Ingrid van Beek, Nick Walsh, Barbara Yeung, Julie Bruneau, Kathy Petoumenos, Kate Dolan, John M Kaldor, Gregory J Dore, Margaret Hellard, Jason Grebely

International Journal of Drug Policy | ELSEVIER | Published : 2015

Grants

Awarded by Australian Government Department of Health


Awarded by National Institute on Drug Abuse of the National Institutes of Health


Awarded by Alberta Innovates


Awarded by NATIONAL INSTITUTE ON DRUG ABUSE


Funding Acknowledgements

The Kirby Institute is funded by the Australian Government Department of Health, under the agreement ID number 2-D3X513. The views expressed in this publication do not necessarily represent the position of the Australian Government. Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under award R01DA015999. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Roche supplied financial support for pegylated IFN-alfa-2a/ribavirin. Gregory Dore and Paul Haber were supported through a National Health and Medical Research Council Practitioner Research Fellowship. Jason Grebely was supported through a National Health and Medical Research Council Career Development Award. Margaret Hellard was supported through a National Health and Medical Research Council Research Fellowship. John Kaldor was supported through a National Health and Medical Research Council Research Fellowship.